top of page

NEW EVENT! Learn more about TAZVERIK at this virtual event!

Updated: Sep 16, 2020

TAZVERIK™ (tazemetostat) is indicated for the treatment of:Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapiesAdult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment optionsThese indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

About the Program

Please join your colleagues for a dynamic discussion about TAZVERIK, sponsored by Epizyme, Inc. and presented by Michael Schuster, MD

27 views0 comments

Recent Posts

See All

Cancer Equity Colloquium 2024

Now more than ever, the presence of social inequities in healthcare is evident. This two-day, hybrid event, the Cancer Equity Colloquium, will address the diverse issues that underlie cancer inequitie


bottom of page